Modified peptide fragments of CAV-1 protein and the use thereof in the treatment of fibrosis
Provided herein are compositions comprising modified caveolin-1 (Cav-1) peptides. Further provided are methods of using the modified Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.
1. A peptide comprising aaEGKASFTTFTVTKGSaa-NH2 (SEQ ID NO: 7) or Ac-aaEGKASFTTFTVTKGSaa-NH2 (SEQ ID NO: 8), wherein: “a” in SEQ ID NO: 7 or SEQ ID NO: 8 is D-alanine; wherein either amino acid sequence may optionally comprise at least one non-standard amino acid substitution; and the peptide is soluble in aqueous solution.
2. The peptide of claim 1 , wherein the peptide sequence of SEQ ID NO: 7 further comprises
at least one amino acid added to the N-terminus.
3. The peptide of claim 1 , wherein
the at least one non-standard substitution is ornithine substituted for lysine (K) in SEQ ID NO: 7 or SEQ ID NO: 8.
4. The peptide of claim 1 , wherein the peptide of SEQ ID NO: 7 further comprises
an N-terminal modification.
5. The peptide of claim 4 , wherein
the N-terminal modification is acylation.
6. The peptide of claim 1 , wherein the peptide comprises the amino acid sequence of aaEGKASETTFTVTKGSaa-NH2 (SEQ ID NO: 7).
7. The peptide of claim 1 , wherein the peptide comprises the amino acid sequence Ac-aaEGKASFTTFTVTKGSaa-NH2 (SEQ ID NO: 8).
8. A composition comprising a peptide of claim 1 .
9. The composition of claim 8 , wherein the peptide is at least 98% pure.
10. The composition of claim 8 , wherein the composition is formulated as a dry powder.
11. A peptide consisting of Ac-aaEGKASFTTFTVTKGSaa-NH2 (SEQ ID NO: 8).